Search results
Results from the WOW.Com Content Network
The RoHS 2 directive (2011/65/EU) contains allowance to add new materials and 4 materials are highlighted for this attention in the original version, the amendment 2015/863 adds four additional substances to Annex II of 2011/65/EU (3/4 of the new restrictions are recommended for investigation in the original directive, ref Para 10 of preamble).
Keppra (levetiracetam) – an anticonvulsant drug which is sometimes used as a mood stabilizer and has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, anxiety disorder, and Alzheimer's disease; Klonopin – anti-anxiety and anti-epileptic medication of the benzodiazepine class
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
This is an alphabetical list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is not exhaustive. All mentioned drugs here are generic names. Not all drugs listed are used regularly in all countries.
For almost half the 94, officials concluded that existing commercial use of the substance is unsafe for human health and/or the environment. Risk management has been initiated for twelve substances since REACH came into force. For 74% of substances (34 out of 46), concerns were demonstrated, but no actual regulatory follow-up has yet been ...
There are currently six substances considered environmentally hazardous by the China RoHS II directive as specified in standard GB/T 26572-2011. [4] The substances followed by its restriction limits are below. Lead, 0.1%; Mercury, 0.1%; Cadmium, 0.01%; Hexavalent chromium, 0.1%; Polybrominated biphenyls, 0.1%; Polybrominated diphenyl ethers, 0.1%
The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II. The drug or other substance has a currently [1] accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
Exposure to the coplanar stereoisomer 3,3',4,4',5,5'-hexabromobiphenyl (but not the non-coplanar stereoisomer) in genetically susceptible mice is known to cause immunotoxicity and disorders related to the central nervous system, and even at doses as low as 2.5 mg/kg, excess neonatal fatalities are observed (LD 50 is from 5–10 mg/kg). [1]